Summary Using untargeted metabolomics (n= 1,162 subjects), the plasma metabolite (m/z=
265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an …

Fecal microbial community changes are associated with numerous disease states, including
cardiovascular disease (CVD). However, such data are merely associative. A causal …

Background: The gut microbiota-dependent metabolite phenylacetylgutamine (PAGln) is
both associated with atherothrombotic heart disease in humans, and mechanistically linked …

Aims Precision microbiome modulation as a novel treatment strategy is a rapidly evolving
and sought goal. The aim of this study is to determine relationships among systemic gut …

Recent studies show gut microbiota-dependent metabolism of dietary phenylalanine into
phenylacetic acid (PAA) is critical in phenylacetylglutamine (PAGln) production, a metabolite …

Objective: The gut microbiota is increasingly being implicated in cardiovascular health.
Metabolites produced by bacteria have been suggested to be mediators in the bacterial …

Rationale: Altered gut microbial composition has been linked to cardiovascular diseases
(CVDs), but its functional links to host metabolism and immunity in relation to CVD …

Despite evidence linking the human microbiome to health and disease, how the microbiota
affects human physiology remains largely unknown. Microbiota-encoded metabolites are …

Commensal bacteria are believed to have important roles in human health. The
mechanisms by which they affect mammalian physiology remain poorly understood, but …

The discovery that gut-microbiota plays a profound role in human health has opened a new
avenue of basic and clinical research. Application of ecological approaches where the …